Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas M Sproule

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Neuromuscular Disorders : NMD|July 30, 2013
The absence of curly hair is associated with a milder phenotype in Giant Axonal NeuropathyLisa A Roth, Bethany L Johnson-Kerner, Jonathan D Marra, et al.
Stroke|March 8, 2003
Monitoring of cerebral vasodilatory capacity with transcranial Doppler carbon dioxide inhalation in patients with severe carotid artery diseaseRandolph S Marshall, Tanja Rundek, Douglas M Sproule, et al.
Archives of Neurology|November 14, 2007
Wolff-Parkinson-White syndrome in Patients With MELASDouglas M Sproule, Petra Kaufmann, Kristen Engelstad, et al.
Journal of Child Neurology|October 5, 2012
Diabetic Ketoacidosis in an Adult Patient With Spinal Muscular Atrophy Type II: Further Evidence of Extraneural Pathology Due to Survival Motor Neuron 1 Mutation?Nicole Holuba Lamarca, Lauren Golden, Rita Marie John, et al.
Neuromuscular Disorders : NMD|May 12, 2009
Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Megan Montgomery, et al.
Journal of Child Neurology|April 15, 2010
Bioelectrical impedance analysis can be a useful screen for excess adiposity in spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Sally L Dunaway, et al.
Journal of Market Access & Health Policy|May 21, 2019
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsDaniel C Malone, Rebecca Dean, Ramesh Arjunji, et al.
Journal of Child Neurology|July 13, 2013
Weakness and fatigue in diverse neuromuscular diseasesJacqueline Montes, Michelle Blumenschine, Sally Dunaway, et al.
Advances in Therapy|March 18, 2019
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1Omar Dabbous, Benit Maru, Jeroen P Jansen, et al.
Journal of Child Neurology|May 17, 2011
Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophyDouglas M Sproule, Megan J Montgomery, Mark Punyanitya, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Neuromuscular Disorders : NMD|July 30, 2013
The absence of curly hair is associated with a milder phenotype in Giant Axonal NeuropathyLisa A Roth, Bethany L Johnson-Kerner, Jonathan D Marra, et al.
Stroke|March 8, 2003
Monitoring of cerebral vasodilatory capacity with transcranial Doppler carbon dioxide inhalation in patients with severe carotid artery diseaseRandolph S Marshall, Tanja Rundek, Douglas M Sproule, et al.
Archives of Neurology|November 14, 2007
Wolff-Parkinson-White syndrome in Patients With MELASDouglas M Sproule, Petra Kaufmann, Kristen Engelstad, et al.
Journal of Child Neurology|October 5, 2012
Diabetic Ketoacidosis in an Adult Patient With Spinal Muscular Atrophy Type II: Further Evidence of Extraneural Pathology Due to Survival Motor Neuron 1 Mutation?Nicole Holuba Lamarca, Lauren Golden, Rita Marie John, et al.
Neuromuscular Disorders : NMD|May 12, 2009
Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Megan Montgomery, et al.
Journal of Child Neurology|April 15, 2010
Bioelectrical impedance analysis can be a useful screen for excess adiposity in spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Sally L Dunaway, et al.
Journal of Market Access & Health Policy|May 21, 2019
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsDaniel C Malone, Rebecca Dean, Ramesh Arjunji, et al.
Journal of Child Neurology|July 13, 2013
Weakness and fatigue in diverse neuromuscular diseasesJacqueline Montes, Michelle Blumenschine, Sally Dunaway, et al.
Advances in Therapy|March 18, 2019
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1Omar Dabbous, Benit Maru, Jeroen P Jansen, et al.
Journal of Child Neurology|May 17, 2011
Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophyDouglas M Sproule, Megan J Montgomery, Mark Punyanitya, et al.
Pageof 4